HC Wainwright Reiterates Buy Rating for Mineralys Therapeutics (NASDAQ:MLYS)
HC Wainwright restated their buy rating on shares of Mineralys Therapeutics (NASDAQ:MLYS – Free Report) in a report issued on Monday morning,Benzinga reports. The firm currently has a $30.00 price objective on the stock. MLYS has been the subject of several other research reports. Guggenheim restated a “buy” rating on shares of Mineralys Therapeutics in […]
HC Wainwright restated their buy rating on shares of Mineralys Therapeutics (NASDAQ:MLYS – Free Report) in a report issued on Monday morning,Benzinga reports. The firm currently has a $30.00 price objective on the stock. MLYS has been the subject of several other research reports. Guggenheim restated a “buy” rating on shares of Mineralys Therapeutics in […]
